Navigation Links
Cell Therapeutics Reaches Agreement to Reacquire Rights to Two Anti-Cancer Compounds
Date:1/13/2014

rapped in the tumor bed, thereby allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel, and that Opaxio may be tumor selective and may not enhance radiation toxicity to normal tissues. Risks that contribute to the uncertain nature of the forward-looking statements include, among others, risks that PIXUVRI may fail to prove safe and effective for the treatment of relapsed or refractory NHL and/or other tumors; that results in future studies or actual results of PIXUVRI may differ from the results of past studies; that CTI may not be able complete a post-marketing study aimed at confirming the clinical benefit observed in the PIX301 trial; that the conditional marketing authorization for PIXUVRI may not be renewed; that CTI may not obtain favorable reimbursement or pricing determinations for PIXUVRI in certain markets in the E.U. as planned, and risks associated with the biopharmaceutical industry in general and with CTI and its product and product candidate portfolio in particular including, among others, risks associated with the following: that CTI cannot predict or guarantee the pace or geography of enrollment of its clinical trials, that CTI may not obtain favorable determinations by other regulatory, patent and administrative governmental authorities, that CTI may experience delays in the commencement of preclinical and clinical studies, risks related to the costs of developing, producing and selling PIXUVRI, Opaxio, and CTI's other product candidates, and other risks, including, without limitation, competitive factors, technological developments, that CTI's operating expenses continue to exceed its net revenues, that CTI may not be able to sustain its current cost controls or further reduce its operating expenses, that CTI may not achieve previously announced goals and objectives as or when projected, that CTI's average net operating burn rate may increase, that CTI will continue to need to raise capital
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sorrento Therapeutics to Present at the Biotech Showcase 2014 and the 7th Annual OneMed Forum SF2014 in San Francisco
2. PhaseRx Appoints Michael Houston, Ph.D., Vice President, Therapeutics Development
3. ImmunoCellular Therapeutics Issues Shareholder Letter Providing Update on ICT-107 Program in Newly Diagnosed Glioblastoma
4. Altheus Therapeutics announces completed enrollment of ZA201, a Phase 2 clinical trial of Zoenasa for distal ulcerative colitis
5. Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy and Immunosuppressants) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018
6. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
7. Flexion Therapeutics Files Registration Statement for Proposed Initial Public Offering
8. G1 Therapeutics to Present at Biotech Showcase 2014
9. Daiichi Sankyo, Virtici and Celdara Medical Announce Collaboration to Identify and Progress High Potential Therapeutics
10. Mast Therapeutics Provides Enrollment Update On Phase 3 "EPIC" Study Of MST-188
11. Revamped Therapies Preventing Visual Impairment Primed to Revolutionize US Retinal Therapeutics Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... SCHOFIELD, Wis. , Dec. 23, 2014 ... and marketer of over-the-counter (OTC) medicinal and healthcare products, ... production of MigraPure® H, a hemp-based, advanced headache relief ... marijuana dispensaries in Colorado , ... . With the MigraPure H Advanced ...
(Date:12/24/2014)... LEXINGTON, Mass. , Dec. 23, 2014 /PRNewswire/ ... GEVA ), a biopharmaceutical company developing therapeutic products ... European Medicines Agency (EMA) of the Marketing Authorization ... The EMA recently granted the company,s request for ... the EMA,s regulatory review time.   ...
(Date:12/24/2014)... Calif. , Dec. 23, 2014 In response ... Doctors, Association of Sierra Leone , Direct ... Leone for the treatment of local health workers ... While a new dedicated Ebola care center was constructed for ... the facility is not available for local Sierra Leonean health ...
Breaking Medicine Technology:PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2
... 2011 Aoxing Pharmaceutical (NYSE Amex: ... focusing on research, development, manufacturing and distribution of ... subsidiary in China, Hebei Aoxing Pharmaceutical Group Company, ... Intellectual Property Office of The People,s Republic of ...
... 2011 IRIDEX Corporation (Nasdaq: IRIX ) ... had issued to IRIDEX a patent applying to a ... ophthalmic surgical procedures. The patent, No. 7,909,816 and titled ... consumable medical devices already in the IRIDEX product line ...
Cached Medicine Technology:Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Naloxone Sublingual Film 2Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Naloxone Sublingual Film 3IRIDEX Granted U.S. Patent for Stepped Angled Laser Handpieces Used in Eye Surgery 2IRIDEX Granted U.S. Patent for Stepped Angled Laser Handpieces Used in Eye Surgery 3
(Date:12/25/2014)... (PRWEB) December 25, 2014 Parker & ... outstanding customer service and affordable quality regarding heating, cooling ... announces recognition in 2014 by the “Queen of Clean” ... has earned an impressive reputation over the years for ... a wide range of contractor services for both homeowners ...
(Date:12/24/2014)... Over 700 toys, that’s what AlignLife clinics ... smiling little faces this holiday that might not have ... donations was given to the various charities as well ... through the year. Some of the charities chosen for ... Shrine's Children's Hospitals, Toys for Tots and Crisis Nurseries, ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 Connie Casad, ... and functional medicine advocate with 30 years of practice ... to evaluate the health benefits of dietary detoxification. The ... new participants following excellent results from test patients who ... asked to explain her interest in conducting the study, ...
(Date:12/24/2014)... 24, 2014 Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ... tort litigation currently underway in Pennsylvania’s Philadelphia Court of ... December 24, 2014, court documents indicate that 1,183 claims ... individuals who developed gynecomastia (male breast growth) and other ... Court indicates that this represents an increase of more ...
(Date:12/24/2014)... 2014 Dr. Vu Ho, a Dallas ... his practice and med-spa with the addition of new ... of cosmetic treatments and services. , “Silk Peel is ... says Dr. Ho. “As a result it can address ... sun spots, discolorations or blemishes.” , Similar to microdermabrasion, ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2
... A new approach to estimating tumour growth based on ... today BioMed Centrals open access journal, Breast Cancer Research. ... of breast cancers which are detected at screening (screen ... simultaneously estimating the growth rate of breast cancer and ...
... May 7 The American Physical,Therapy Association (APTA) ... and consumer groups to advocate for funding for ... Seniors Act., In remarks during today,s "Falls ... Falls Free Coalition representative Bonita,Lynn Beattie, PT, MPT, ...
... $174 million, up 187% from same quarter a year ago, ... segment grew 29%, - Net income of $3.7 million, or ... attributable to management bonuses and $350,000 of ... - Cash flow of $13.8 million after $2.2 ...
... Healthcare,Acquisition Corp. (the "Company") (OTC Bulletin Board: OHAQ) ... of the Company and,its proposed plan of liquidation, ... 16, 2008, at the special meeting of stockholders ... the Company has set May 7, 2008 as ...
... blocking brain molecules similar to those in marijuana could ... to a new study from MITs Picower Institute for ... an appetite stimulant, and a new class of anti-obesity ... and awaiting approval for use in the United Stateswork ...
... University of Alabama at Birmingham (UAB) this month became ... cancer radiation therapy. The new technique can turn a ... patients. , Additionally, the new therapy saves healthy human ... the same or better than other radiotherapy techniques, according ...
Cached Medicine News:Health News:Breast cancer tumors grow faster in younger women 2Health News:Physical Therapist Stresses Funding for Falls Prevention at National Safety Council Briefing 2Health News:Providence Service Corporation Announces 187% Revenue Increase in First Quarter of 2008 2Health News:Providence Service Corporation Announces 187% Revenue Increase in First Quarter of 2008 3Health News:Providence Service Corporation Announces 187% Revenue Increase in First Quarter of 2008 4Health News:Providence Service Corporation Announces 187% Revenue Increase in First Quarter of 2008 5Health News:Providence Service Corporation Announces 187% Revenue Increase in First Quarter of 2008 6Health News:Providence Service Corporation Announces 187% Revenue Increase in First Quarter of 2008 7Health News:Providence Service Corporation Announces 187% Revenue Increase in First Quarter of 2008 8Health News:Providence Service Corporation Announces 187% Revenue Increase in First Quarter of 2008 9Health News:Providence Service Corporation Announces 187% Revenue Increase in First Quarter of 2008 10Health News:Oracle Healthcare Acquisition Corp. Announces Stockholder Approval of Proposed Dissolution and Plan of Liquidation 2Health News:MIT study suggests caution on new anti-obesity drug in kids 2Health News:UAB first in US to offer speedier precise cancer radiotherapy 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: